hig.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard-cite-them-right
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • sv-SE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • de-DE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Differences in trial knowledge and motives for participation among cancer patients in phase 3 clinical trials
Uppsala universitet, Centrum för forsknings- och bioetik.
Uppsala universitet, Centrum för forsknings- och bioetik.
Uppsala universitet; University of Bergen, Bergen, Norway.
Uppsala universitet, Vårdvetenskap.
Vise andre og tillknytning
2015 (engelsk)Inngår i: European Journal of Cancer Care, ISSN 0961-5423, E-ISSN 1365-2354, Vol. 25, nr 3, s. 516-523Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

While participants in clinical oncology trials are essential for the advancement of cancer therapies, factors decisive for patient participation have been described but need further investigation, particularly in the case of phase 3 studies. The aim of this study was to investigate differences in trial knowledge and motives for participation in phase 3 clinical cancer trials in relation to gender, age, education levels and former trial experience. The results of a questionnaire returned from 88 of 96 patients (92%) were analysed using the Mann-Whitney U-test. There were small, barely relevant differences in trial knowledge among patients when stratified by gender, age or education. Participants with former trial experience were less aware about the right to withdraw. Male participants and those aged ≥65 years were significantly more motivated by a feeling of duty, or by the opinions of close ones. Men seem more motivated than women by external factors. With the awareness that elderly and single male participants might be a vulnerable group and participants with former trial experience are less likely to be sufficiently informed, the information consent process should focus more on these patients. We conclude that the informed consent process seems to work well, with good results within most subgroups.

sted, utgiver, år, opplag, sider
2015. Vol. 25, nr 3, s. 516-523
Emneord [en]
adults, cancer, clinical trials, patient education, patient information, phase 3 trials
HSV kategori
Identifikatorer
URN: urn:nbn:se:hig:diva-20510DOI: 10.1111/ecc.12319ISI: 000375066900018PubMedID: 25904313Scopus ID: 2-s2.0-84928316987OAI: oai:DiVA.org:hig-20510DiVA, id: diva2:865754
Tilgjengelig fra: 2015-05-08 Laget: 2015-10-29 Sist oppdatert: 2018-03-13bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMedScopus

Personposter BETA

Silén, Marit

Søk i DiVA

Av forfatter/redaktør
Silén, Marit
I samme tidsskrift
European Journal of Cancer Care

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 439 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard-cite-them-right
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • sv-SE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • de-DE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf